|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/03/24 BioXcel Therapeutics, Inc. S-8 4/03/24 4:99K Toppan Merrill/FA |
Document/Exhibit Description Pages Size
1: S-8 Registration Statement - Securities for an HTML 56K
Employee Benefit Plan
2: EX-5.1 Opinion of Counsel re: Legality HTML 14K
3: EX-23.1 Consent of Expert or Counsel HTML 5K
4: EX-FILING FEES Filing Fees HTML 19K
| Page | (sequential) | (alphabetic) | ↑Top | ||
|---|---|---|---|---|---|
| 1 | 1st Page – Filing Submission | ||||
| " | 24.1 | ||||
| " | Power of Attorney (included on the signature page of the Registration Statement) | ||||
As filed with the Securities and Exchange Commission on April 3, 2024
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
BioXcel Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 82-1386754 | |
|
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
555 Long Wharf Drive
(Address of Principal Executive Offices) (Zip Code)
BioXcel Therapeutics, Inc. 2020 Incentive Award Plan
BioXcel Therapeutics, Inc. 2020 Employee Stock Purchase Plan
(Full title of the plans)
Vimal Mehta, Ph.D.
Chief Executive Officer
BioXcel Therapeutics, Inc.
555 Long Wharf Drive
(Name and address of agent for service)
(475) 238-6837
(Telephone number, including area code, of agent for service)
Copies to:
Peter N. Handrinos
Keith L. Halverstam
Ellen Smiley
Latham & Watkins LLP
200 Clarendon Street
(617) 948-6060
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ¨ | Accelerated filer | ¨ | |
| Non-accelerated filer | x | Smaller reporting company | x | |
| Emerging growth company | ¨ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨
EXPLANATORY NOTE
This Registration Statement on Form S-8 is being filed with the Securities and Exchange Commission (the “Commission”) for the purpose of registering an additional 1,496,498 shares of common stock, par value $0.001 per share (the “Common Stock”), of BioXcel Therapeutics, Inc. (the “Company”), issuable under the following employee benefit plans for which a registration statement of the Company on Form S-8 (File Nos. 333-238580, 333-266922 and 333-270652) is effective: (i) the BioXcel Therapeutics, Inc. 2020 Incentive Award Plan (the “2020 Plan”) and (ii) the BioXcel Therapeutics, Inc. 2020 Employee Stock Purchase Plan (the “2020 ESPP”).
INCORPORATION BY REFERENCE
Pursuant to General Instruction E of Form S-8, the contents of the above-referenced prior registration statements are incorporated into this Registration Statement by reference to the extent not modified or superseded hereby or by any subsequently filed document, which is incorporated by reference herein or therein.
Item 8. EXHIBITS.
Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New Haven, State of Connecticut, on this 3rd day of April, 2024.
| BioXcel Therapeutics, Inc. | ||
| By | /s/ Vimal Mehta | |
| Vimal Mehta | ||
| Chief Executive Officer, President and Director | ||
Each of the undersigned officers and directors of the registrant hereby severally constitutes and appoints Vimal Mehta, Ph.D. and Richard Steinhart, and each of them singly (with full power to each of them to act alone), as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them, for him or her and in his or her name, place and stead, and in any and all capacities, to file and sign any and all amendments, including post-effective amendments, to this registration statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith and about the premises as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof. This power of attorney shall be governed by and construed with the laws of the State of Delaware and applicable federal securities laws.
Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities held on the dates indicated.
| Signature | Title | Date | ||
| /s/ Vimal Mehta, Ph.D. | Chief Executive Officer, President and Director | April 3, 2024 | ||
| Vimal Mehta, Ph.D. | (principal executive officer) | |||
| /s/ Richard Steinhart | Chief Financial Officer | April 3, 2024 | ||
| Richard Steinhart | (principal financial officer and principal accounting officer) | |||
| /s/ Peter Mueller, Ph.D. | Chairman of the Board of Directors | April 3, 2024 | ||
| Peter Mueller, Ph.D. | ||||
| /s/ June Bray | Director | April 3, 2024 | ||
| June Bray | ||||
| /s/ Sandeep Laumas, M.D. | Director | April 3, 2024 | ||
| Sandeep Laumas, M.D. | ||||
| /s/ Michael Miller | Director | |||
| Michael Miller | April 3, 2024 | |||
| /s/ Michal Votruba, M.D., Ph.D. | Director | April 3, 2024 | ||
| Michal Votruba, M.D., Ph.D. |
| This ‘S-8’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on / Effective on: | 4/3/24 | None on these Dates | ||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/17/23 BioXcel Therapeutics, Inc. S-8 3/17/23 4:93K Toppan Merrill/FA 8/16/22 BioXcel Therapeutics, Inc. S-8 8/16/22 5:101K Toppan Merrill/FA 8/10/21 BioXcel Therapeutics, Inc. 10-Q 6/30/21 56:5.1M Toppan Merrill Bridge/FA 8/14/20 BioXcel Therapeutics, Inc. 10-Q 6/30/20 59:4.2M Toppan Merrill Bridge/FA 5/21/20 BioXcel Therapeutics, Inc. S-8 5/21/20 3:171K Toppan Merrill/FA 5/21/20 BioXcel Therapeutics, Inc. 8-K:5,9 5/20/20 3:263K Toppan Merrill/FA 3/13/18 BioXcel Therapeutics, Inc. 8-K:5,8,9 3/07/18 6:337K Toppan Merrill/FA 2/26/18 BioXcel Therapeutics, Inc. S-1/A 2/23/18 6:4.7M Toppan Merrill-FA |